Week in Review: Jacobson Pharma Raises $85 Million in Hong Kong IPO

Jacobson Pharma, Hong Kong's largest generic company, completed an $85 million IPO on the Hong Kong exchange; TenNor Therapeutics of Suzhou announced a $25 million Series B financing for its novel dual-acting antibiotic platform; Golden Meditech will invest $20 million in an autoimmune-focused JV that combines its China cord blood banking operation and Houston's MD Anderson Cancer Center; Shenzhen Nuokang raised $10 million to support its continuous, non-invasive blood pressure measurement device; PharmaLegacy, a Shanghai preclinical CRO, formed a strategic alliance with regulatory specialist Normalline of Beijing; China private equity firm FountainVest Partners closed its third fund with $2.1 billion of committed capital; Hua Medicine of Shanghai successfully completed a Phase II trial of its fourth-generation oral Glucokinase Activator for type 2 diabetes; Huons Global, a Korean pharma, expects approval to begin production at its China manufacturing facility; the China National GeneBank, located in Shenzhen, opened this week to collect genetic information from all forms of biology; and WuXi Biologics, a division of WuXi AppTec, completed construction on the first phase of its $150 million commercial-scale cGMP biologics manufacturing facility. More details.... Stock Symbols: (HK: 2633) (HK: 00801; TW: 910801) Share this with colleagues: // //